BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
32997133
Number of visits today
3640
Number of downloads
16182932
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Nakamura T, Kawakami K, Nomura M, Sato Y, Hyodo M, Hatakeyama H, Hayakawa Y, Harashima H. Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.03.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Zhu H, Lin L, Zhao W, Zhu X, Pang DW, Liu AA. Redox Imbalance Triggered Intratumoral Cascade Reaction for Tumor "turn on" Imaging and Synergistic Therapy. Small 2023;:e2206272. [PMID: 36683231 DOI: 10.1002/smll.202206272] [Reference Citation Analysis]
2 Chen S, Peng A, Chen M, Zhan M. Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1093240] [Reference Citation Analysis]
3 Fekrirad Z, Barzegar Behrooz A, Ghaemi S, Khosrojerdi A, Zarepour A, Zarrabi A, Arefian E, Ghavami S. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy. Cancers 2022;14:3698. [DOI: 10.3390/cancers14153698] [Reference Citation Analysis]
4 Khalifa AM, Nakamura T, Sato Y, Sato T, Hyodo M, Hayakawa Y, Harashima H. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. Int J Pharm 2022;624:122034. [PMID: 35863595 DOI: 10.1016/j.ijpharm.2022.122034] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345